Bolt Biotherapeutics Q3 EPS $(0.43) Beats $(0.50) Estimate, Sales $2.53M Beat $1.72M Estimate

Author: Benzinga Newsdesk | November 09, 2023 06:23pm
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 25.86 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $2.53 million which beat the analyst consensus estimate of $1.72 million by 46.98 percent. This is a 19.70 percent increase over sales of $2.11 million the same period last year.

Posted In: BOLT